Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Raw Materials (2022 - 2025)

Gyre Therapeutics (GYRE) has disclosed Raw Materials for 4 consecutive years, with $970000.0 as the latest value for Q4 2025.

  • Quarterly Raw Materials rose 22.17% to $970000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $970000.0 through Dec 2025, up 22.17% year-over-year, with the annual reading at $970000.0 for FY2025, 22.17% up from the prior year.
  • Raw Materials for Q4 2025 was $970000.0 at Gyre Therapeutics, down from $1.1 million in the prior quarter.
  • The five-year high for Raw Materials was $1.2 million in Q2 2025, with the low at $724000.0 in Q1 2024.
  • Average Raw Materials over 4 years is $1.0 million, with a median of $1.0 million recorded in 2022.
  • The sharpest move saw Raw Materials dropped 13.6% in 2024, then surged 61.46% in 2025.
  • Over 4 years, Raw Materials stood at $1.1 million in 2022, then fell by 12.97% to $919000.0 in 2023, then fell by 13.6% to $794000.0 in 2024, then rose by 22.17% to $970000.0 in 2025.
  • According to Business Quant data, Raw Materials over the past three periods came in at $970000.0, $1.1 million, and $1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.